Phase 1/2/3

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

Beyond the clinical data, ALX Oncology's latest update reveals a masterclass in strategic finance and leadership, positioning it for critical milestones.

With a strong cash runway to 2028 and key data expected, Aclaris is advancing a multi-asset portfolio against complex immuno-inflammatory diseases.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

With FDA clearance for IKS04, Iksuda Therapeutics unveils a novel co-dosing strategy to deliver a potent payload past notorious tumor barriers.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

As its lead therapy for NCFB enters clinical trials, Revagenix promotes a seasoned drug developer to steer its patient-centric strategy in the chronic disease market.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.